Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple…
Quince entered into a definitive agreement for a private placement financing to raise up to $187 million in gross proceeds, which includes $115 million in…
Quince Therapeutics (QNCX) acquires Orphai and secures up to $187M PIPE. The Series C non-voting convertible preferred plus warrant structure preserves…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Quince Therapeutics acquired Orphai Therapeutics, a clinical-stage biotech, bringing in lead asset LAM-001 (inhaled rapamycin) for rare pulmonary diseases including PH-ILD and bronchiolitis obliterans syndrome. Concurrent private placement of up to $187 million ($115M upfront plus up to $72M warrants) led by Balyasny Asset Management.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Quince Therapeutics, Inc. / Orphai Therapeutics Inc. (this deal) | 2026 | — | — |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 2026 deals · Cardiovascular deals